Ausgabe 2/2015
Inhalt (13 Artikel)
Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies
Jeanne Tie, Jayesh Desai
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model
Olivier Trédan, Magali Lacroix-Triki, Séverine Guiu, Marie-Ange Mouret-Reynier, Jérôme Barrière, François-Clément Bidard, Antoine-Laurent Braccini, Olivier Mir, Christian Villanueva, Philippe Barthélémy
Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists
Jean-Baptiste Rey, Vincent Launay-Vacher, Christophe Tournigand
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis
Hanno Niess, Peter Camaj, Andrea Renner, Ivan Ischenko, Yue Zhao, Stefan Krebs, Josef Mysliwietz, Carsten Jäckel, Peter J. Nelson, Helmut Blum, Karl-Walter Jauch, Joachim W. Ellwart, Christiane J. Bruns
Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports
Adeline Egron, Pascale Olivier-Abbal, Aurore Gouraud, Samy Babai, Sandrine Combret, Jean-Louis Montastruc, Emmanuelle Bondon-Guitton
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
Donald L. Smith, Jaime Acquaviva, Manuel Sequeira, John-Paul Jimenez, Chaohua Zhang, Jim Sang, Richard C. Bates, David A. Proia
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC
Cecile Bosc, Gilbert R. Ferretti, Jacques Cadranel, Clarisse Audigier-Valette, Benjamin Besse, Fabrice Barlesi, Chantal Decroisette, Sylvie Lantuejoul, François Arbib, Denis Moro-Sibilot
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
David F. Heigener, José Rodrigues Pereira, Enriqueta Felip, Juraj Mazal, Lyudmila Manzyuk, Eng Huat Tan, Ofer Merimsky, Barbara Sarholz, Regina Esser, Ulrich Gatzemeier
Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma
Inga Peters, Natalia Dubrowinskaja, Hossein Tezval, Mario W. Kramer, Christoph A. von Klot, Jörg Hennenlotter, Arnulf Stenzl, Ralph Scherer, Markus A. Kuczyk, Jürgen Serth
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)
M. Donini, S. Buti, S. Lazzarelli, R. Bozzetti, L. Rivoltini, C. Camisaschi, C. Castelli, A. Bearz, C. Simonelli, G. Lo Re, R. Mattioli, C. Caminiti, R. Passalacqua
Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study
Jiaping Li, Fujun Zhang, Jianyong Yang, Yingqiang Zhang, Yu Wang, Wenzhe Fan, Yonghui Huang, Wei Wang, Henry Ran, Shi Ke
Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature
Isabel Ihnenfeld Arciénega, Patrick Imesch, Daniel Fink, Konstantin J. Dedes
Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology
Sohita Dhillon